Apollomics 公布 Uproleselan 在中國治療復發或難治性急性髓系白血病患者的第 3 期銜接性試驗的主要結果
December 20, 2024 13:13 ET
|
Apollomics Inc.
福特斯城，加州, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「該公司」) 是一家後期臨床生物製藥公司，開發多種腫瘤候選藥物以解決難治性和對治療有抗藥性的癌症。該公司今日公布了其藥物 uproleselan 在中國針對復發或難治性急性髓系白血病患者進行的第 3 期銜接性試驗結果。...
Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果
December 20, 2024 13:13 ET
|
Apollomics Inc.
加利福尼亚州福斯特城, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (简称 “Apollomics” 或 “公司”) 是一家后期临床生物制药公司，开发了多种肿瘤候选药物，致力于治疗难治性和耐药性癌症。该公司今天公布了其在中国对复发性或难治性急性髓系白血病患者进行的 uproleselan III...
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
December 20, 2024 08:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
December 10, 2024 16:05 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
November 21, 2024 08:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
September 16, 2024 08:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 16:05 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
August 14, 2024 06:00 ET
|
Apollomics Inc.
Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9...
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
August 13, 2024 08:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
August 08, 2024 16:05 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...